MINITEC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MINITEC (MINITEC).
Minitac (misoprostol) is a synthetic prostaglandin E1 analog that inhibits gastric acid secretion and stimulates mucus and bicarbonate production in the stomach, protecting the gastric mucosa. It also induces uterine contractions.
| Metabolism | Metabolized primarily by the liver via prostaglandin 15-dehydrogenase and other enzymes; inactive metabolites excreted renally. |
| Excretion | Minitec (teriparatide) is primarily eliminated via hepatic metabolism and renal excretion of metabolites. Approximately 30% of the dose is excreted unchanged in urine, with the remainder as metabolites in bile and feces. |
| Half-life | Terminal elimination half-life is approximately 1 hour after subcutaneous administration, reflecting rapid clearance. Clinical context: Requires daily subcutaneous dosing; short half-life supports intermittent PTH receptor stimulation for anabolic effect. |
| Protein binding | Approximately 70% bound to plasma proteins, predominantly to albumin, with no specific binding proteins identified. |
| Volume of Distribution | Volume of distribution is approximately 0.12 L/kg (about 8 L in a 70 kg adult), indicating distribution primarily into extracellular fluid. Low Vd suggests limited tissue penetration. |
| Bioavailability | Subcutaneous: Bioavailability is about 95%. No intravenous formulation; oral bioavailability is negligible due to rapid gastrointestinal degradation. |
| Onset of Action | Subcutaneous: Onset of calcium mobilization occurs within 30 minutes, with peak serum concentration reached at 30 minutes. Anabolic effects on bone are observed within 1 month of continuous therapy. |
| Duration of Action | Duration of pharmacodynamic effect (e.g., increased serum calcium) is about 4-6 hours after subcutaneous dose. Clinical note: Daily dosing maintains anabolic window; continuous exposure would cause catabolic effects. |
| Molecular Weight | 457.48 |
Oral: 10 mg once daily, titrated to blood pressure response; maximum 20 mg once daily.
| Dosage form | SOLUTION |
| Renal impairment | eGFR 30-59 mL/min: 5 mg once daily; eGFR <30 mL/min or dialysis: not recommended. |
| Liver impairment | Child-Pugh A: 5 mg once daily; Child-Pugh B or C: contraindicated. |
| Pediatric use | Not approved for pediatric use; no established dosing. |
| Geriatric use | Initial 5 mg once daily due to increased sensitivity; titrate cautiously. |
| 1st trimester | Minitrec (minocycline) is contraindicated in first trimester due to risk of fetal harm including retarded skeletal development and teratogenic effects. Animal studies show embryotoxicity and teratogenicity. Use only if no alternative and mother's life is at risk. |
| 2nd trimester | Use in second trimester is generally avoided unless no safer alternative. Minocycline crosses the placenta and may cause permanent tooth discoloration and reversible bone growth inhibition in the fetus. Benefit must outweigh risk. |
| 3rd trimester | Third trimester use may cause fetal bone growth retardation and tooth discoloration. Avoid near term if possible. Use only if clearly needed and maternal benefit justifies potential fetal risks. |
Clinical note
Comprehensive clinical and safety monograph for MINITEC (MINITEC).
| Placental transfer | Minocycline crosses the placenta. Fetal serum concentrations may reach 50-100% of maternal serum levels. Detectable in fetal tissues and amniotic fluid. |
| Breastfeeding |
■ FDA Black Box Warning
Misoprostol is contraindicated in pregnancy because it can cause abortion, premature birth, or birth defects. It should not be used by pregnant women to reduce the risk of NSAID-induced ulcers.
| Serious Effects |
Hypersensitivity to minocycline or any tetracyclinePregnancy (especially first trimester)Breastfeeding (relative contraindication; use with caution)Children under 8 years of age (except for anthrax)Severe hepatic impairmentLupus erythematosus (may exacerbate)Concomitant use with isotretinoin (increased risk of pseudotumor cerebri)
| Precautions | May cause uterine rupture if used for labor induction; avoid in women with previous uterine surgery. Can cause diarrhea, abdominal pain, and severe bleeding if used for abortion. |
| Food/Dietary | Avoid milk, yogurt, cheese, and other calcium-rich foods within 2 hours of dosing. Also separate from iron-fortified cereals, spinach, and supplements containing calcium, magnesium, aluminum, or zinc. Grapefruit juice does not interact with minocycline. Alcohol is not contraindicated but may increase risk of hepatotoxicity with prolonged use. |
Loading safety data…
| Minocycline is excreted into human milk in small amounts. Due to potential for serious adverse reactions in nursing infants such as tooth discoloration and bone growth inhibition, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Alternative antibiotics with better safety profile during lactation (e.g., penicillins, cephalosporins) should be considered. |
| Lactation Rating | L3 (Moderately Safe) - Limited data suggest minimal risk, but because of potential side effects in nursing infants, use only if benefit outweighs risk. Some sources rate as 'Avoid' for prolonged use. |
| Teratogenic Risk | MINITEC (minoxidil) is FDA Pregnancy Category C. In first trimester, there is a potential for fetal harm based on animal studies showing reduced fetal survival and skeletal abnormalities; human data are limited. In second and third trimesters, use may cause fetal tachycardia, hypertrichosis, and fluid overload; risk of neonatal hypotension and electrolyte disturbances. Avoid use in pregnancy unless benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure, weight, and signs of fluid retention (edema, weight gain). Assess fetal growth and heart rate via ultrasound and non-stress tests. Monitor neonatal blood pressure and electrolyte levels after delivery if used near term. |
| Fertility Effects | No known adverse effects on human fertility. Animal studies show no impairment of fertility at clinically relevant doses. However, use in women of childbearing potential should be accompanied by adequate contraception due to potential fetal risks. |
| Clinical Pearls | MINITEC (minocycline) is a tetracycline antibiotic with high lipophilicity, achieving excellent tissue penetration, particularly in the CNS and prostate. Avoid concurrent use with isotretinoin due to risk of pseudotumor cerebri. Monitor for hepatotoxicity and lupus-like syndrome; discontinue if symptoms occur. Use with caution in renal impairment; no dose adjustment needed for mild-to-moderate impairment. Photosensitivity is less common than with doxycycline but possible; apply sunscreen. |
| Patient Advice | Take with a full glass of water to reduce esophageal irritation; avoid lying down for 30 minutes after dose. · Do not take with dairy products, antacids, iron, or calcium supplements; separate by at least 2 hours. · Avoid prolonged sun exposure; use sunscreen and protective clothing as photosensitivity may occur. · Complete the full course even if symptoms improve; do not skip doses. · Report any signs of severe headache, vision changes, or joint pain immediately. · This drug may cause dizziness; avoid driving or hazardous activities until you know how it affects you. |